Aberrant Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts, Assessed by Next-Generation Flow Cytometry, Is a Negative Predictor for Deep Response Post Autologous Transplantation in Multiple Myeloma; A Prospective Study in 199 Patients.
Multiple Myeloma
autologous stem cell transplantation
minimal residual disease
next-generation flow cytometry
stem cell grafts
tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Aug 2021
11 Aug 2021
Historique:
received:
09
06
2021
revised:
09
07
2021
accepted:
09
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
High-dose chemotherapy with autologous stem cell support (ASCT) is the standard of care for eligible newly diagnosed Multiple Myeloma (MM) patients. Stem cell graft contamination by aberrant plasma cells (APCs) has been considered a possible predictive marker of subsequent clinical outcome, but the limited reports to date present unclear conclusions. We prospectively estimated the frequency of graft contamination using highly sensitive next-generation flow cytometry and evaluated its clinical impact in 199 myeloma patients who underwent an ASCT. Contamination (con+) was detected in 79/199 patients at a median level 2 × 10
Identifiants
pubmed: 34439201
pii: cancers13164047
doi: 10.3390/cancers13164047
pmc: PMC8391595
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : GSRT Operational program "Competitiveness, Entrepreneurship, & Innovation (EPAnEK) 2014-2020
ID : My-BIOTag; T1EDK-01837
Références
Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):445-452
pubmed: 32284296
Leukemia. 2009 Jan;23(1):10-24
pubmed: 18843284
Curr Cancer Drug Targets. 2017;17(9):806-818
pubmed: 28201978
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
J Clin Oncol. 2020 Mar 10;38(8):784-792
pubmed: 31770060
J Cancer Res Clin Oncol. 2009 Apr;135(4):637-42
pubmed: 18941780
Blood Cancer J. 2019 Apr 8;9(4):44
pubmed: 30962422
Blood. 2018 Dec 6;132(23):2456-2464
pubmed: 30249784
Blood Cancer J. 2018 May 24;8(5):46
pubmed: 29795385
Blood. 2016 Jun 23;127(25):3165-74
pubmed: 27118453
Int J Mol Sci. 2021 Apr 24;22(9):
pubmed: 33923357
Cancers (Basel). 2020 Nov 04;12(11):
pubmed: 33158030
Semin Oncol. 2016 Dec;43(6):676-681
pubmed: 28061985
Cancer J. 2019 Jan/Feb;25(1):2-10
pubmed: 30694854
Cancer Treat Rev. 2020 Jan;82:101929
pubmed: 31770695
Immunol Rev. 2015 Jan;263(1):160-72
pubmed: 25510276
Drugs. 2017 Apr;77(5):505-520
pubmed: 28205024
Biomed Res Int. 2014;2014:982504
pubmed: 24895639
Lancet. 2010 Dec 18;376(9758):2075-85
pubmed: 21146205
Front Oncol. 2020 May 27;10:860
pubmed: 32537439
J Biomed Biotechnol. 2012;2012:157496
pubmed: 23093834
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Br J Haematol. 2019 Sep;186(6):807-819
pubmed: 31364160
Haematologica. 2020 Jul 23;105(10):2358-2367
pubmed: 33054076
Leukemia. 2017 Oct;31(10):2094-2103
pubmed: 28104919
Semin Hematol. 2018 Jan;55(1):44-50
pubmed: 29759154
Cancers (Basel). 2021 Jan 09;13(2):
pubmed: 33435306
Haematologica. 2007 Aug;92(8):1083-90
pubmed: 17640853
Blood. 2020 Aug 20;136(8):936-945
pubmed: 32325490
Hemasphere. 2019 Oct 01;3(6):e300
pubmed: 31976475
J Clin Oncol. 2013 Sep 10;31(26):3279-87
pubmed: 23897961
Haematologica. 2014 Mar;99(3):408-16
pubmed: 24598852
Blood. 2011 Mar 17;117(11):3041-4
pubmed: 21098740
Cancer Cell. 2014 Jan 13;25(1):91-101
pubmed: 24434212
Bone Marrow Transplant. 1997 Aug;20(3):205-10
pubmed: 9257888
Ann Oncol. 2021 Mar;32(3):309-322
pubmed: 33549387
Ann Hematol. 2020 Jun;99(6):1257-1264
pubmed: 32382768
J Cancer Res Clin Oncol. 2005 Apr;131(4):214-8
pubmed: 15616828
J Clin Oncol. 2001 Sep 1;19(17):3771-9
pubmed: 11533101
Cells. 2019 Nov 13;8(11):
pubmed: 31766279